Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant - Summary - MDSpire
Advertisement
Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant
To evaluate the efficacy of an ASCT-free approach with 24 cycles of Dara-KRd in patients with newly diagnosed multiple myeloma (NDMM) regardless of ASCT eligibility, highlighting its potential benefits over traditional methods.
Key Findings:
40 out of 42 patients were evaluable for the primary endpoint, indicating a robust sample for analysis.
The median age of participants was 58 years, with 57% having high-risk cytogenetic abnormalities, underscoring the study's relevance to challenging patient populations.
The median number of treatment cycles received was 23, suggesting good adherence to the treatment protocol.
Interpretation:
The study demonstrates the potential efficacy of Dara-KRd in achieving deep responses in NDMM without the need for ASCT, particularly in patients with high-risk features, aligning with trends in current research.
Limitations:
Small sample size with only 42 enrolled patients, limiting generalizability.
Single-arm design limits comparison with other treatment modalities, introducing potential biases.
Conclusion:
Daratumumab-based quadruplet therapy shows promise for NDMM patients, achieving significant response rates without ASCT, warranting further investigation into long-term outcomes and comparative effectiveness.
by Benjamin A. Derman, Jennifer Cooperrider, Jacalyn Rosenblatt, David E. Avigan, Murtuza Rampurwala, David Barnidge, Ajay Major, Theodore Karrison, Ken Jiang, Aubrianna Ramsland, Tadeusz Kubicki, Andrzej J. Jakubowiak
